Castleknight Management LP
-12.85%
3M Return
$37.670
+1.367 (+3.63%)收盘时
Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
Phibro Animal Health Corp (PAHC) is a good buy right now due to its strong recent financial performance and positive growth outlook. The current price is $37.67, and the company reported a 37% increase in adjusted net income for Q4 2026, reaching $35 million. Additionally, the forward P/E ratio is 13.83, indicating potential undervaluation compared to future earnings. However, the main risk is the analyst downgrade from Citi, which lowered the price target significantly to $44, citing regulatory headwinds.
Citi
$44
2026-05-14
Citi
2026-05-14
目标价
$44
Citi
$44
2026-05-13
Citi
2026-05-13
目标价
$44
Citi
$62
2026-04-15
Citi
2026-04-15
目标价
$62
Morgan Stanley
$49
2026-02-06
Morgan Stanley
2026-02-06
目标价
$49
JPMorgan
$50
2025-11-07
JPMorgan
2025-11-07
目标价
$50

Phibro Animal Health Reports Strong Q4 and FY Results

Phibro Animal Health Corporation Reports FY 2026 Financial Results

Phibro Animal Declares Quarterly Dividend of $0.12

Tilray Brands Reports Larger Than Expected Quarterly Loss

Bruker Corporation Shares Surge 50.3% Amid Strong Growth
Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Phibro Animal Health Corp (PAHC) is a good buy right now due to its strong recent financial performance and positive growth outlook. The current price is $37.67, and the company reported a 37% increase in adjusted net income for Q4 2026, reaching $35 million. Additionally, the forward P/E ratio is 13.83, indicating potential undervaluation compared to future earnings. However, the main risk is the analyst downgrade from Citi, which lowered the price target significantly to $44, citing regulatory headwinds.
6 analysts cover PAHC: 1 rate it Buy, 2 Hold and 3 Sell. The average price target is 47.50.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。